Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $2.2 million.

  • Seres Therapeutics' Cash from Operations rose 10636.1% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.1 million, marking a year-over-year increase of 8533.64%. This contributed to the annual value of -$148.6 million for FY2024, which is 2663.31% down from last year.
  • As of Q3 2025, Seres Therapeutics' Cash from Operations stood at $2.2 million, which was up 10636.1% from -$13.3 million recorded in Q2 2025.
  • Seres Therapeutics' 5-year Cash from Operations high stood at $127.7 million for Q3 2021, and its period low was -$76.6 million during Q1 2023.
  • Its 5-year average for Cash from Operations is -$24.9 million, with a median of -$39.7 million in 2021.
  • Examining YoY changes over the last 5 years, Seres Therapeutics' Cash from Operations showed a top increase of 59386.07% in 2021 and a maximum decrease of 18930.11% in 2021.
  • Over the past 5 years, Seres Therapeutics' Cash from Operations (Quarter) stood at -$51.9 million in 2021, then dropped by 1.98% to -$52.9 million in 2022, then grew by 10.2% to -$47.5 million in 2023, then rose by 18.14% to -$38.9 million in 2024, then surged by 105.67% to $2.2 million in 2025.
  • Its Cash from Operations stands at $2.2 million for Q3 2025, versus -$13.3 million for Q2 2025 and $26.9 million for Q1 2025.